Testing effectiveness (Phase 2)Study completedNCT02860000
What this trial is testing
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Who this might be right for
Estrogen Receptor StatusHER2/Neu NegativeInvasive Breast Carcinoma+6 more
Mayo Clinic 96